Anticonvulsants in the treatment of major depressive disorder: An overview

Harvard Review of Psychiatry

Volumn 17, Issue 4, 2009, Pages 231-241

  Vigo, Daniel V ^a,b,c,d,e   Baldessarini, Ross J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

^c Instituto de Investigaciones Farmacologicas   (Argentina)

^d Outpatient Unit   (Argentina)

^e Mental Health Center   (Argentina)

Author keywords

Anticonvulsants; Antidepressants; Depression; Major depression; Unipolar depression

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; ETIRACETAM; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; OXCARBAZEPINE; PHENYTOIN; PLACEBO; SEDATIVE AGENT; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ADULT; AGITATION; BIPOLAR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; MONOTHERAPY; MOOD DISORDER; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SUICIDE; WEIGHT REDUCTION;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CARBAMAZEPINE; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID;

EID: 68649123338     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220903129814     Document Type: Review

References (104)

1. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005;62:1097-1106 (Pubitemid 41396935)
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
3. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005;58:175-189 (Pubitemid 41112265)
4. van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. Int J Geriatr Psychiatry 2007;22:613-626 (Pubitemid 47180373)
5. Wang PS, Simon G, Kessler RC. Economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 2003;12:22-33. (Pubitemid 36675445)
6. Casacalenda N, Perry JC, Looper K. Remission in major depressive disorder: comparison of pharmacotherapy, psychotherapy, and control conditions. Am J Psychiatry 2002;159:1354-1360 (Pubitemid 34832717)
7. Baldessarini RJ. Drug therapy of depression and anxiety disorders. In: Brunton L, Lazo J, Parker K, eds. Goodman and Gilman's The pharmacological basis of therapeutics. New York: McGraw-Hill, 2005:429-459
8. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143:415-426 (Pubitemid 41341413)
9. Cipriani A, Barbui C, Brambilla P, Furukawa TA, Hotopf M, Geddes JR. Are all antidepressants really the same? The case of fluoxetine: systematic review. J Clin Psychiatry 2006;67:850-864 (Pubitemid 44049083)
10. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45-76. (Pubitemid 351317657)
11. Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment inmajor depression. Harv Rev Psychiatry 1998;5:293-306. (Pubitemid 28182534)
12. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: systematic review. Lancet 2003;361:653-661 (Pubitemid 36246547)
13. Baldessarini RJ, Pompili M, Tondo L, et al. Antidepressants and suicidal behavior: are we hurting or helping. Clin Neuropsychiatry 2005;2:73-75
14. Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006;26:203-207
15. Simon RI, Hales RE. Textbook of suicide assessment and management. Washington, DC: American Psychiatric Publishing, 2006:1-32.
16. Baldessarini RJ, Tondo L, Strombom IM, et al. Ecological studies of antidepressant treatment and suicidal risks. Harv Rev Psychiatry 2007;15:133-145 (Pubitemid 47237774)
17. Hammad TA, Laughren TP, Racoosin JA. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-339 (Pubitemid 43345358)
18. Laughren TP. Overview for a meeting of the Psychopharmacology Drug Advisory Committee (PDAC) concerning suicidal risk in trials of antidepressant drugs in juvenile and adult patients, 2006. At http://www.fda.gov/ohrms/ dockets/ac/06/briefing/2006-4272b1-index.htm
19. Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: systematic review of observational studies. CMAJ 2009;180:291-297
20. Friedman RA, Leon AC. Expanding the black box; depression, antidepressants and the risk of suicide. N Engl J Med 2007;356:2343-2346 (Pubitemid 46883767)
21. Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. Efficacy of antidepressants in depressed children and adolescents: meta-analysis. Br J Psychiatry 2008;193:10-17
22. Tondo L, Vázquez G, Baldessarini RJ. Antidepressant-associated mania and hypomania: meta-analytic review. Acta Psychiatr Scand (2009, in press).
23. Grunhaus L, Schreiber S, Dolberg OT, Polak D, Dannon PN. Randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol Psychiatry 2003;53:324-331 (Pubitemid 36175546)
24. Marangell LB, Martinez M, Jurdi RA, Zboyan H. Neurostimulation therapies in depression: review of new modalities. Acta Psychiatr Scand 2007;116:174-181
25. Nierenberg AA, Katz J, Fava M. Critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr Clin North Am 2007;30:13-29. (Pubitemid 46386307)
26. Neimat JS, Hamani C, Giacobbe P, et al. Neural stimulation successfully treats depression in patients with prior ablative cingulotomy. Am J Psychiatry 2008;165:687-693 (Pubitemid 351810536)
27. McNeely HE, Mayberg HS, Lozano AM, Kennedy SH. Neuropsychological impact of Cg25 deep brain stimulation for treatment-resistant depression: preliminary results over 12 months. J Nerv Ment Dis 2008;196:405-410
28. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 2008;11:253-259 (Pubitemid 351350599)
29. Davis JM, Janicak PG, Hogan DM. Mood-stabilizers in the prevention of recurrent affective disorders: meta-analysis. Acta Psychiatr Scand 1999;100:406-417
30. Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003;28:1374-1382 (Pubitemid 41070909)
31. Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003;23:484-495
32. Ketter TA, Wang PW, Becker OV, Nowakowska C, Yang YS. Diverse roles of anticonvulsants in bipolar disorders. Ann Clin Psychiatry 2003;15:95-108. (Pubitemid 38101801)
33. Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004;65 (suppl 10):28-35.
34. Trivedi MH, Fava M, Wisniewski SR, et al; STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252
35. Normann C, Hummel B, Scharer LO, Horn M, Grunze H, Walden J. Lamotrigine as adjunct to paroxetine in acute depression: placebo-controlled, double-blind study. J Clin Psychiatry 2002;63:337-344 (Pubitemid 34456362)
36. Barbosa L, Berk M, Vorster M. Double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003;64:403-407 (Pubitemid 36547282)
37. Nickel C, Lahmann C, Tritt K, et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. J Affect Disord 2005;87:243-252 (Pubitemid 41039946)
38. Shapira B, Nemets B, Trachtenberg A, Belmaker RH. Phenytoin as an augmentation for SSRI failures: small controlled study. J Affect Disord 2006;96:123-126 (Pubitemid 44548044)
39. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry 1986;143:29-34.
40. Small JG. Anticonvulsants in affective disorders. Psychopharmacol Bull 1990;26:25-36.
41. Rybakowski JK, Suwalska A, Chlopocka-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 1999;40:134-139 (Pubitemid 29435736)
42. Frye MA, Ketter TA, Kimbrell TA, et al. Placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-614 (Pubitemid 30953799)
43. Nemets B, Bersudsky Y, Belmaker RH. Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. J Clin Psychiatry 2005;66:586-590 (Pubitemid 40733700)
44. Stuppaeck CH, Barnas C, Schwitzer J, Fleischhacker WW. Carbamazepine in the prophylaxis ofmajor depression: 5-year follow-up. J Clin Psychiatry 1994;55:146-150 (Pubitemid 24143120)
45. Davis LL, Kabel D, Patel D, et al. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 1996;32:647-652 (Pubitemid 26428268)
46. Debattista C, Solomon A, Arnow B, Kendrick E, Tilston J, Schatzberg AF. Efficacy of divalproex sodium in the treatment of agitation associated with major depression. J Clin Psychopharmacol 2005;25:476-479 (Pubitemid 41368372)
47. Carpenter LL, Schecter JM, Tyrka AR, et al. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry 2006;67:66-71.
48. Gabriel A. Lamotrigine adjunctive treatment in resistant unipolar depression: open, descriptive study. Depress Anxiety 2006;23:485-488 (Pubitemid 44917668)
49. Pasquini M, Picardi A, Speca A, et al. Combining an SSRI with an anticonvulsant in depressed patients with dysphoric mood: open study. Clin Pract Epidemol Ment Health 2007;3:3-4. (Pubitemid 46306364)
50. Schindler F, Anghelescu IG. Lithium vs. lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open label study. Int Clin Psychopharmacol 2007;22:179-182 (Pubitemid 46559875)
51. Emrich HM, Dose M, von Zerssen D. Use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985;8:243-250 (Pubitemid 15088800)
52. McElroy SL, Keck PE Jr, Pope HG Jr. Sodium valproate: use in primary psychiatric disorders. J Clin Psychopharmacol 1987;7:16-24. (Pubitemid 17005665)
53. Kobayashi T, Kishimoto A, Inagaki T. Treatment of periodic depression with carbamazepine. Acta Psychiatr Scand 1988;77:364-367
54. Hayes SG. Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry 1989;50 (suppl):35-39 (Pubitemid 19092383)
55. Pies R, Adler DA, Ehrenberg BL. Sleep disorders and depression with atypical features: response to valproate. J Clin Psychopharmacol 1989;9:352-357 (Pubitemid 19242959)
56. Cullen M, Mitchell P, Brodaty H, et al. Carbamazepine for treatment-resistant melancholia. J Clin Psychiatry 1991;52:472-476
57. Corrigan FM. Sodium valproate augmentation of fluoxetine or fluvoxamine effects. Biol Psychiatry 1992;31:1178-1179
58. De la Fuente JM, Mendlewicz J. Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression. Biol Psychiatry 1992;32:369-374
59. Schatzberg AF, Debattista C, DeGolia S. Valproate in the treatment of agitation associated with major depression. Psychiatr Ann 1996;26(suppl):S470-3. (Pubitemid 126718944)
60. Zarate CA Jr, Tohen M, Baraibar G. Combined valproate or carbamazepine and electroconvulsive therapy. Ann Clin Psychiatry 1997;9:19-25. (Pubitemid 27425016)
61. Deltito JA, Levitan J, Damore J, Hajal F, Zambenedetti M. Naturalistic experience with the use of divalproex sodium on an in-patient unit for adolescent psychiatric patients. Acta Psychiatr Scand 1998;97:236-240 (Pubitemid 28083024)
62. Dietrich DE, Emrich HM. Anticonvulsants to augment antidepressant medication. J Clin Psychiatry 1998;59(suppl 5): 51-59
63. Yasmin S, Carpenter LL, Leon Z, Siniscalchi JM, Price LH. Adjunctive gabapentin in treatment-resistant depression: retrospective chart review. J Affect Disord 2001;63:243-247 (Pubitemid 32200521)
64. Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 2002;63:737-741
65. Carpenter LL, Leon Z, Yasmin S, Price LH. Do obese depressed patients respond to topiramate? A retrospective chart review. J Affect Disord 2002;69:251-255 (Pubitemid 34722892)
66. Schmidt do Prado-Lima PA, Bacaltchuck J. Topiramate in treatment-resistant depression and binge-eating disorder. Bipolar Disord 2002;4:271-273
67. Rocha FL, Hara C. Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol 2003;18:97-99
68. Hantouche EG, Akiskal HS, Lancrenon S, Chatenet-Duchene L. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study. J Affect Disord 2005;84:243-249
69. Maltese T. Adjunctive lamotrigine in major depression. Am J Psychiatry 1999;156:1833-1934
70. Gutierrez RL, McKercher R, Galea J, Jamison KL. Lamotrigine augmentation strategy for patients with treatment resistant depression. CNS Spectr 2005;10: 800-805 (Pubitemid 41534642)
71. Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton L, Lazo J, Parker K, eds. Goodman and Gilman's The pharmacological basis of therapeutics. New York: McGraw-Hill, 2005:461-500.
72. Bowden CL, Calabrese JR, Sachs GS, et al. Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400. (Pubitemid 36403000)
73. Calabrese JR, Bowden CL, Sachs GS, et al. Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-1024 (Pubitemid 37158246)
74. Goodwin GM, Bowden CL, Calabrese JR, et al. Pooled analysis of two placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65:432-441
75. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: review of its use in bipolar disorder. Drugs 2003;63:2029-2050 (Pubitemid 37229087)
76. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Spotlight on lamotrigine in bipolar disorder. CNS Drugs 2004;18: 63-67
77. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008;10:323-333
78. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Seizure 2008;17:166-171
79. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008;70:2152-2158
80. Newport DJ, Stowe Z, Viguera AC, et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord 2008;10:432-436
81. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002;63:1012-1019
82. Obrocea GV, Dunn RM, Frye MA, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002;51:253-260
83. Winsberg ME, DeGolia SG, Strong CM, Ketter TA. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001;67:207-212 (Pubitemid 34183352)
84. Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM. Diagnostic guidelines for bipolar depression: probabilistic approach. Bipolar Disord 2008;10:144-152
85. Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligomenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006;59:1078-1086 (Pubitemid 43849652)
86. Schapel G, Chadwick D. Tiagabine and nonconvulsive status epilepticus. Seizure 1996;5:153-156
87. Ettinger AB, Bernal OG, Andriola MR, et al. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia 1999;40:1159-1162 (Pubitemid 29372634)
88. Suppes T, Chisholm KA, Dhavale D, et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord 2002;4:283-289
89. Gordon A, Price LH. Mood stabilization and weight-loss with topiramate. Am J Psychiatry 1999;156:968-969
90. Macdonald KJ, Young LT. Newer antiepileptic drugs in bipolar disorder: rationale for use and role in therapy. CNS Drugs 2002;16:549-562
91. Kruszewski SP, Klotz SG. Effects of topiramate. Am J Psychiatry 2007;164:526-527
92. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006;8:15-27. (Pubitemid 43356017)
93. Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: placebo controlled pilot study. J Psychopharmacol 2005;19:551-553 (Pubitemid 41392309)
94. Muralidharan A, Bhagwagar Z. Potential of levetiracetam in mood disorders: a preliminary review. CNS Drugs 2006 20:969-979 (Pubitemid 44912706)
95. Mazza M, Martini A, Scoppetta M, Mazza S. Effect of levetiracetam on depression and anxiety in adult epileptic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:539-543 (Pubitemid 351178974)
96. French J, Edrich P, Cramer JA. Systematic review of the safety profile of levetiracetam: new antiepileptic drug. Epilepsy Res 2001;47:77-90. (Pubitemid 32973650)
97. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology 2003;61:704-706 (Pubitemid 37082613)
98. Ghaemi SN, Zablotsky B, Filkowski MM, et al. An open prospective study of zonisamide in acute bipolar depression. J Clin Psychopharmacol 2006;26:385-388 (Pubitemid 44187640)
99. Ghaemi SN, Shirzadi AA, Klugman J, Berv DA, Pardo TB, Filkowski MM. Is adjunctive open-label zonisamide effective for bipolar disorder? J Affect Disord 2008;105: 311-314
100. Ghaemi SN, Baldessarini RJ. The manic-depressive spectrum and mood stabilization: Kraepelin's ghost. Psychother Psychosom 2007;76:65-69 (Pubitemid 46145634)
101. Akiskal HS, Benazzi F. Continuous distribution of atypical depressive symptoms between major depressive and bipolar II disorders: dose-response relationship with bipolar family history. Psychopathology 2008;41:39-42. (Pubitemid 350146912)
102. Phelps J, Angst J, Katzow J, Sadler J. Validity and utility of bipolar spectrum models. Bipolar Disord 2008;10:179-193
103. Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. 2nd ed. New York: Oxford University Press, 2007;8-25.
104. United States Food and Drug Administration. Statistical review and evaluation: antiepileptic drugs and suicidality. 2008. At http://www.fda.gov/ ohrms/dockets/